Welcome to our dedicated page for Palvella Therapeutics news (Ticker: PVLA), a resource for investors and traders seeking the latest updates and insights on Palvella Therapeutics stock.
Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company developing investigational topical therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatments. News about Palvella often centers on progress across its QTORIN™ platform, including clinical trial milestones, regulatory designations, and pipeline expansion.
The company’s lead candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is being studied in the Phase 3 SELVA trial for microcystic lymphatic malformations and in the Phase 2 TOIVA trial for cutaneous venous malformations, with additional development planned in clinically significant angiokeratomas. Updates on these programs include topline clinical results, details on trial design, and commentary from investigators and company leadership on efficacy and safety findings.
Palvella also reports news on its second product candidate, QTORIN™ pitavastatin, for disseminated superficial actinic porokeratosis, including announcements of its selection as a new QTORIN-derived therapy and plans for Phase 2 clinical evaluation. Regulatory and grant-related news, such as FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations and Orphan Products Grant funding, provide additional context on how regulators view the unmet need in the company’s target indications.
Investors and observers following PVLA news can expect coverage of quarterly financial results, corporate updates, leadership appointments in areas like medical affairs and innovation, and participation in healthcare conferences. This news stream helps track how Palvella advances its investigational programs, manages its development priorities, and positions its QTORIN™ platform within the rare dermatologic disease landscape, while consistently noting that its product candidates remain investigational and unapproved.
Palvella Therapeutics (Nasdaq: PVLA) closed an upsized public offering on February 27, 2026, selling 1,840,000 common shares including full exercise of a 240,000-share underwriter option at $125.00 per share, generating $230.0 million in gross proceeds.
Palvella said it will use net proceeds to advance development of QTORIN rapamycin and QTORIN pitavastatin, support R&D, and for working capital and general corporate purposes. The shares were offered under a Form S-3 shelf registration declared effective January 29, 2026.
Palvella Therapeutics (Nasdaq: PVLA) priced an upsized public offering of 1,600,000 shares at $125.00 per share, with a 30-day underwriter option for an additional 240,000 shares. Gross proceeds are expected to be approximately $200 million before fees. The offering is expected to close on or about February 27, 2026.
Palvella intends to use net proceeds to fund development of QTORIN rapamycin and QTORIN pitavastatin, plus working capital and general corporate purposes.
Palvella Therapeutics (Nasdaq: PVLA) announced a proposed underwritten public offering of $150.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $22.5 million.
Palvella intends to use net proceeds to support development of QTORIN rapamycin and QTORIN pitavastatin, plus working capital and R&D. The offering is subject to market and other conditions and will be filed on Form S-3.
Palvella Therapeutics (NASDAQ: PVLA) reported positive topline Phase 3 SELVA results for QTORIN™ 3.9% rapamycin gel in microcystic lymphatic malformations. In the ITT (n=49) mean mLM-IGA improvement was +2.13 (p<0.001); key secondary mLM-MCSS improved -3.36 (p<0.001).
At Week 24, 95% improved and 86% were “Much”/“Very Much Improved”; systemic rapamycin <2 ng/mL; 98% continued into extension. Palvella plans an NDA in H2 2026 with potential U.S. approval H1 2027.
Palvella Therapeutics (Nasdaq: PVLA) will host a live webcast conference call on February 24, 2026 at 8:00am ET to discuss topline results from the Phase 3 SELVA trial of QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.
The company plans to release topline results at approximately 6:30am ET prior to the call. A replay will be available about 2 hours after the call and archived for 90 days in the Events & Presentations section of Palvella’s website.
Palvella Therapeutics (Nasdaq: PVLA) announced publication of a systematic review in Clinical and Experimental Dermatology synthesizing real-world evidence for topical statins in porokeratosis.
The review covers 24 studies (95 patients), reports mostly partial clinical benefit, underscores genetic mevalonate-pathway rationale, and notes no FDA-approved therapies. Palvella expects QTORIN™ pitavastatin to enter Phase 2 in H2 2026.
Palvella Therapeutics (NASDAQ: PVLA) provided a 2026 corporate update outlining progress across its late-stage QTORIN platform for rare skin diseases and vascular malformations. The Phase 3 SELVA trial of QTORIN rapamycin for microcystic lymphatic malformations enrolled 51 patients (vs 40 target) and expects topline results in March 2026; an NDA submission is planned in H2 2026 if results are positive. A positive Phase 2 in cutaneous venous malformations (TOIVA) reported 73% improvement and a Preliminary Breakthrough Advice meeting with FDA is requested for Q1 2026. Additional Phase 2 starts and a new QTORIN candidate are planned in H2 2026. IP extends through 2038 for rapamycin and potential 2046 for pitavastatin. Leadership hires strengthen commercial and technical teams.
Palvella Therapeutics (Nasdaq: PVLA) announced the appointment of Vimal Patel, PharmD as Senior Vice President of Medical Affairs effective Jan. 7, 2026. Patel brings more than 25 years of dermatology and immunology medical affairs leadership across late‑stage development, launches, and lifecycle management.
He will lead medical strategy, KOL engagement, disease state awareness, and medical education for Palvella’s QTORIN™ programs targeting serious, rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations.
Palvella Therapeutics (Nasdaq: PVLA) announced the FDA Fast Track Designation for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of angiokeratomas.
The designation is intended to facilitate development and expedite review; QTORIN™ rapamycin may be eligible for Accelerated Approval and Priority Review if criteria are met. Palvella plans a Phase 2 study of ~10–20 patients, with an FDA meeting in H1 2026 and study initiation expected in H2 2026. Angiokeratomas affect an estimated more than 50,000 diagnosed U.S. patients and currently have no FDA‑approved therapies.
Palvella Therapeutics (NASDAQ: PVLA) reported positive topline Phase 2 TOIVA results for QTORIN™ 3.9% rapamycin gel in cutaneous venous malformations on Dec 15, 2025. Key findings at Week 12: 73% (11/15) improved on the Overall cVM-IGA and 67% (10/15) were rated “Much” or “Very Much Improved.” Multiple clinician- and patient-reported endpoints reached nominal statistical significance. QTORIN was generally well tolerated with no drug-related serious adverse events and systemic rapamycin levels below assay quantification. Palvella plans near-term FDA discussions on Breakthrough Therapy and a Phase 3 pivotal study; FDA previously granted Fast Track designation.